A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome
Conditions: Relapsed Non Hodgkin Lymphoma; Chronic Lymphocytic Leukemia; Refractory Chronic Lymphocytic Leukemia; Richter Syndrome; MYC Amplification; MYC Overexpression; MYC Translocation Intervention: Drug: VIP152 Sponsor: Vincerx Pharma, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Chronic Leukemia | Chronic Lymphocytic Leukemia | Leukemia | Lymphoma | Pharmaceuticals | Research | Study | Translocation